The TMS Treatment for Postoperative Headache in GH Tumor
The TMS Treatment for Postoperative Headache in GH Tumor
Headache is a very common main complaint of patients with GH pituitary tumor, which has
 seriously affected the normal work and life of patients. Although the current surgery and
 drugs have a certain effect on patients with headache, the overall effect is not satisfied.
 However, the use of COX-2 inhibitors, non-steroidal anti-inflammatory drugs and other
 analgesics are only effective for some patients with headaches, and long-term use has adverse
 reactions. Therefore, it is necessary to seek new treatments for postoperative headaches in
 patients with GH pituitary tumors. Transcranial magnetic stimulation (TMS) modulates the
 excitability of the underlying cerebral cortex by applying a rapidly changing magnetic field
 on the surface of the scalp. It is a relatively simple and safe method. It is currently
 approved for treating depression, migraine, obsessive-compulsive disorder, and Alzheimer's
 disease. Several small clinical studies have proven that rTMS can be used to prevent and
 treat Headache. Therefore, this study aims to observe the efficacy and safety of TMS in the
 treatment of postoperative headache in patients with GH pituitary tumors.
Inclusion Criteria:

 -  Patients with GH tumor who have undergone transnasal pituitary tumor resection or
 craniotomy for pituitary tumor resection in the past (3 months or more), aged between
 18 and 60 years old, regardless of gender;

 -  Preoperative glucose tolerance test (OGTT) simultaneously determines that the
 trough value of GH is greater than 1ng/ml, and the level of IGF-1 is greater than
 the upper limit of the age-sex-matched normal value; ③. Biochemical remission is
 achieved after surgery, that is, the random GH value is less than 1ng/ml, and the
 IGF-1 level is within the normal range of age and gender matching; ④. The patient
 still has headaches after the operation, the duration of each attack is more than
 4 hours, and the attack is more than 3 times per month; ⑤. The patient is in a
 headache attack period; ⑥. A clear consciousness, able to understand and sign an
 informed consent form.

 Exclusion Criteria:

 -  Patients who are being treated with somatostatin and bromocriptine;

 -  Patients with other intracranial organic diseases;

 -  Pregnant women and children who cannot express;

 -  Patients with other malignant tumors;

 -  Participate in other clinical research in the same period; ⑥.
 Patients with severe medical complications, such as heart, lung,
 kidney, liver and other diseases, severe hypertension or poor
 blood pressure control, hyperglycemia, blood diseases;

 -  Those with mental illness who cannot cooperate well with the
 experiment;

 -  Patients with acute infection or open wounds; ⑨.
 Acetaminophen is contraindicated (hemolytic anemia,
 severe liver and kidney dysfunction) or allergic to its
 components; ⑩. Patients with contraindications to
 transcranial magnetic stimulation: patients or users who
 have implanted cardiac pacemakers, implantable
 defibrillators and neurostimulators together; those who
 have a history of epilepsy; wear electronic products
 (such as insulin Pumps, Holter, etc.).